GLP3-CARGI research monograph — the retatrutide + cagrilintide combination rationale

GLP3-CARGI is a vendor blend, not a studied drug product — it pairs two separate weight-management
research compounds. The value of this monograph is in being explicit about what is and isn't known
about the combination, since the component evidence does not transfer automatically to the blend.

Composition.
The blend combines retatrutide — a triple incretin agonist acting at the GIP, GLP-1, and
glucagon receptors — with cagrilintide, a long-acting amylin (and calcitonin-receptor) analog.
See the dedicated retatrutide and cagrilintide monographs for each component's pharmacology and
trial record.

Combination rationale.
The research rationale is mechanistic complementarity: incretin/glucagon multi-agonism and amylin
agonism drive satiety and metabolic effects through different pathways, so pairing them is
hypothesised to be additive. This mirrors the logic of the cagrilintide-plus-incretin programs
being studied in industry (e.g. amylin analog plus a GLP-1 agonist), but GLP3-CARGI specifically —
retatrutide with cagrilintide — is a community/vendor combination, not a formulation with its own
clinical record.

What the research shows.
There are no published clinical trials of this specific two-compound combination. The component
compounds each have their own (very different) evidence bases — retatrutide has phase-2 obesity
data; cagrilintide has been studied with semaglutide — but combination-specific efficacy and
safety for retatrutide + cagrilintide is unstudied. Treat any additive claim as hypothesis.

Research protocols (combination context).
Combination dosing is more variable and less characterised than single-compound dosing, and no
trial-derived protocol exists for this pair. The two components have different half-lives and
titration considerations (see each monograph). Report figures only at the single-component level
and frame the combination as unstudied.

Quality & sourcing notes.
A blend COA should verify the identity and quantity of each component separately (mass
spectrometry per peptide) and state the ratio — a single "total mg" figure is not sufficient to
know what is in the vial. Underdosing or omission of one component is a blend-specific failure mode.

*Research-use note: This monograph is an educational summary of the published research literature.
GLP3-CARGI is a vendor blend, not an approved drug; its components are research compounds described
here for research context only. Nothing here is medical advice or a usage recommendation.*